---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-000641"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T02:47:55.900482+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics updates patent portfolio for ATR and WEE1 inhibitor programs

## Summary
- ATR inhibitor program: 4 granted US patents, 1 pending US application, 1 provisional; 19 granted non-US patents, 16 pending non-US applications.
- Granted patents expire 2035-2037; pending applications may extend exclusivity to 2044.
- Lead ATR inhibitor ATRN-119 in Phase 1 ABOYA-119 trial for solid tumors with DDR mutations.
- WEE1 inhibitor program: 1 pending US application, 12 pending non-US applications; if granted, expire 2043.
- Lead WEE1 inhibitor APR-1051 in Phase 1 ACESOT-1051 trial for advanced/metastatic solid tumors.

## SEC filing metadata
- accession: 0001558370-25-000641
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837025000641/0001558370-25-000641-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837025000641/apre-20250205x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-000641
- JSON: https://secwatch.observer/filing/0001558370-25-000641.json
- Plain text: https://secwatch.observer/filing/0001558370-25-000641.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.